Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (421-430 of 607) with videos related to

Pageof 61
Sort By:
Radiology|August 3, 2004
CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumoniaSujal R Desai, Srihari Veeraraghavan, David M Hansell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
Molecular and Cellular Biology|July 1, 2006
Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptorsXu Shi-Wen, Fernando Rodríguez-Pascual, Santiago Lamas, et al.
Journal of Scleroderma and Related Disorders|June 8, 2018
Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial designMichael Hughes, Andrew Tracey, Monica Bhushan, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Molecular Biology of the Cell|March 30, 2004
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblastsXu Shi-Wen, Yunliang Chen, Christopher P Denton, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Rheumatology (Oxford, England)|February 8, 2020
Patient experiences of digital ulcer development and evolution in systemic sclerosisMichael Hughes, John D Pauling, Jennifer Jones, et al.
The Lancet. Rheumatology|November 21, 2022
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational studyKristina E N Clark, Eszter Csomor, Corrado Campochiaro, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 13, 2021
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness ScoreMasataka Kuwana, Yannick Allanore, Christopher P Denton, et al.
Pageof 61

Showing results (421-430 of 607) with videos related to

Sort By:
Pageof 61
Radiology|August 3, 2004
CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumoniaSujal R Desai, Srihari Veeraraghavan, David M Hansell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2020
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic SclerosisVivek Nagaraja, Marco Matucci-Cerinic, Daniel E Furst, et al.
Molecular and Cellular Biology|July 1, 2006
Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptorsXu Shi-Wen, Fernando Rodríguez-Pascual, Santiago Lamas, et al.
Journal of Scleroderma and Related Disorders|June 8, 2018
Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial designMichael Hughes, Andrew Tracey, Monica Bhushan, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Molecular Biology of the Cell|March 30, 2004
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblastsXu Shi-Wen, Yunliang Chen, Christopher P Denton, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Rheumatology (Oxford, England)|February 8, 2020
Patient experiences of digital ulcer development and evolution in systemic sclerosisMichael Hughes, John D Pauling, Jennifer Jones, et al.
The Lancet. Rheumatology|November 21, 2022
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational studyKristina E N Clark, Eszter Csomor, Corrado Campochiaro, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 13, 2021
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness ScoreMasataka Kuwana, Yannick Allanore, Christopher P Denton, et al.
Pageof 61